OverviewChartNewsTraderScreen

BVT Call 875 REGN 20.09.2024/  DE000VM2R3S0  /

EUWAX
2024-05-29  8:49:01 AM Chg.-0.12 Bid1:13:31 PM Ask1:13:31 PM Underlying Strike price Expiration date Option type
1.12EUR -9.68% 1.10
Bid Size: 17,000		 1.14
Ask Size: 17,000		 Regeneron Pharmaceut... 875.00 USD 2024-09-20 Call
GlobeNewswire 05-28 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 05-23 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 05-22 Invivyd Elects Two New Independent Members to its Board of Directors
GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire 05-20 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire 05-20 Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire 05-17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire 05-14 Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire 05-14 Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire 05-10 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire 05-09 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire 05-08 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire 05-07 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire 05-06 Regeneron Announces Investor Conference Presentations
GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire 04-26 Medigene AG reports Financial Results and Business Update for Q1 2024
GlobeNewswire 04-25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire 04-23 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire 04-22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire 04-18 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...